Loading company…
Phagos Biotech develops bacteriophage-based treatments for bacterial infections.
Phagos Biotech is developing antibacterial treatments using bacteriophages, natural predators of bacteria. Its approach aims to provide alternatives to antibiotics for infectious diseases. Founded in 2021, the company is based in Paris, France. In October 2025, it raised EUR 25 million in Series A funding co-led by Capagro and Cap Horn, with returning and new investors also participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in